| Record Information |
| Version |
3.5 |
| Creation Date |
2006-10-16 06:27:59 -0600 |
| Update Date |
2013-05-15 15:21:53 -0600 |
| HMDB ID |
HMDB05007 |
| Secondary Accession Numbers |
|
| Metabolite Identification |
| Common Name |
Simvastatin |
| Description |
Simvastatin is a hypolipidemic drug belonging to the class of pharmaceuticals called 'statins'. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; Simvastatin is a powerful lipid-lowering drug that can decrease low density lipoprotein (LDL) levels by up to 50 percent. It is used in doses of 5 mg up to 80 mg. Higher doses (160 mg) have been found to be too toxic, while giving only minimal benefit in terms of lipid lowering. There is no real effect on HDL and triglyceride levels. Simvastatin (INN) is a hypolipidemic drug belonging to the class of pharmaceuticals called 'statins'. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; The drug is the form of an inactive lactone that is hydrolized after ingestion to produce the active agent. It is a white, nonhygroscopic, crystalline powder that is practically insoluble in water, and freely soluble in chloroform, methanol and ethanol; Ezetimibe/simvastatin is a combination product to lower lipids and marketed as Vytorin. |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- (+)-Simvastatin
- Cholestat
- Denan
- Eucor
- Kolestevan
- Lipex
- Lipinorm
- Liponorm
- Lipovas
- Lodales
- Modutrol
- Nor-Vastina
- Pepstatin
- Rechol
- Simcor
- Simovil
- Simvastatin
- Simvastatin lactone
- Simvotin
- Sinvacor
- Sinvascor
- Sivastin
- Statin
- Synvinolin
- Valemia
- Velostatin
- Zocor
- Zocord
|
| Chemical Formula |
C25H38O5 |
| Average Molecular Weight |
418.5662 |
| Monoisotopic Molecular Weight |
418.271924326 |
| IUPAC Name |
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate |
| Traditional IUPAC Name |
simvastatin |
| CAS Registry Number |
79902-63-9 |
| SMILES |
[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC |
| InChI Identifier |
InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1 |
| InChI Key |
RYMZZMVNJRMUDD-HGQWONQESA-N |
| Chemical Taxonomy |
| Kingdom |
Organic Compounds |
| Super Class |
Lipids |
| Class |
Fatty Acid Esters |
| Sub Class |
N/A |
| Other Descriptors |
- Aliphatic Heteropolycyclic Compounds
- a small molecule(Cyc)
|
| Substituents |
- Carboxylic Acid Ester
- Cyclohexene
- Dicarboxylic Acid Derivative
- Lactone
- Oxane
- Secondary Alcohol
|
| Direct Parent |
Fatty Acid Esters |
| Ontology |
| Status |
Detected and Quantified |
| Origin |
|
| Biofunction |
- Anticholesteremic Agents
- Antilipemic Agents
- Cell signalling
- Fuel and energy storage
- Fuel or energy source
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Membrane integrity/stability
|
| Application |
- Nutrients
- Pharmaceutical
- Stabilizers
- Surfactants and Emulsifiers
|
| Cellular locations |
|
| Physical Properties |
| State |
Solid |
| Experimental Properties |
| Property |
Value |
Reference |
| Melting Point |
135 - 138 °C |
Not Available |
| Boiling Point |
Not Available |
Not Available |
| Water Solubility |
1.22e-02 g/L |
Not Available |
| LogP |
4.68 |
HANSCH,C ET AL. (1995) |
|
| Predicted Properties |
|
| Spectra |
|
Not Available
|
| Biological Properties |
| Cellular Locations |
|
| Biofluid Locations |
|
| Tissue Location |
|
| Pathways |
Not Available
|
| Normal Concentrations |
|
| Blood |
Detected and Quantified |
|
0.044 +/- 0.011 uM |
Adult (>18 years old) |
Both |
Normal
|
|
|
| Abnormal Concentrations |
|
Not Available |
| Associated Disorders and Diseases |
| Disease References |
None |
| Associated OMIM IDs |
None |
| External Links |
| DrugBank ID |
DB00641  |
| DrugBank Metabolite ID |
Not Available |
| Phenol Explorer Compound ID |
Not Available |
| Phenol Explorer Metabolite ID |
Not Available |
| FoodDB ID |
FDB023580 |
| KNApSAcK ID |
Not Available |
| Chemspider ID |
49179  |
| KEGG Compound ID |
Not Available |
| BioCyc ID |
Not Available |
| BiGG ID |
Not Available |
| Wikipedia Link |
Simvastatin  |
| NuGOwiki Link |
HMDB05007  |
| Metagene Link |
HMDB05007  |
| METLIN ID |
2443  |
| PubChem Compound |
54454  |
| PDB ID |
Not Available |
| ChEBI ID |
9150  |
| References |
| Synthesis Reference |
Willard, Alvin K.; Smith, Robert L.; Hoffman, William F. 6(R)-[2-(8-acyloxy-2-methyl-6-methyl (or hydrogen)-polyhydro-1-naphthyl)ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones, the hydroxy acid forms of these pyranones, salts and esters thereof, and a pharmaceutical antihypercholesterolemic composition containing them. Eur. Pat. Appl. (1981), 54 pp. CODEN: EPXXDW EP 33538 19810812 CAN 95:219968 AN 1981:619968 |
| Material Safety Data Sheet (MSDS) |
Download (PDF)
|
| General References |
- Mahboobi SK, Shohat EZ, Jellinek SP, Rose M: Systemic infections can decrease the threshold of statin-induced muscle injury. South Med J. 2006 Apr;99(4):403-4.
Pubmed: 16634254
- Antons KA, Williams CD, Baker SK, Phillips PS: Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006 May;119(5):400-9.
Pubmed: 16651050
- Tsivgoulis G, Spengos K, Karandreas N, Panas M, Kladi A, Manta P: Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med. 2006 Jul 24;166(14):1519-24.
Pubmed: 16864763
- Finsterer J, Zuntner G: Rhabdomyolysis from Simvastatin triggered by infection and muscle exertion. South Med J. 2005 Aug;98(8):827-9.
Pubmed: 16144183
- Soininen K, Niemi M, Kilkki E, Strandberg T, Kivisto KT: Muscle symptoms associated with statins: a series of twenty patients. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):51-4.
Pubmed: 16433891
- Davidson MH, Maccubbin D, Stepanavage M, Strony J, Musliner T: Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol. 2006 Jan 15;97(2):223-8. Epub 2005 Nov 21.
Pubmed: 16442367
- Hellinger FJ, Encinosa WE: Inappropriate drug combinations among privately insured patients with HIV disease. Med Care. 2005 Sep;43(9 Suppl):III53-62.
Pubmed: 16116309
|